Activation of SGK1 has been associated with cardiac hypertrophy, in which increased phosphorylated SGK1 and phosphorylated FoxO1, a downstream target of SGK1, were observed following cardiomyocyte treatment with phenylephrine (PE), a cardiac hypertrophic stimulant. Here, SGK1 is linked to cardiac hypertrophy.